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Despite extensive basic and clinical research on immune 
checkpoint regulatory pathways, little is known about the 
effects of the ionic tumour microenvironment on immune 
checkpoint expression and function.
We screened effects of ion channel modulating
compounds on IDO1 activity. Here, we describe a 
+ +mechanistic link between Na /K  ATPase inhibition by 
cardiac glycosides and activity of indoleamine-2',3'-
dioxygenase (IDO1), a well-characterized immune 
checkpoint.
IDO1 catalyses the rate-limiting step of tryptophan 
catabolism and inhibits the immune response to the 
tumour by local depletion of tryptophan, an amino acid
essential for anabolic functions in cancer and T cells.
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Cardiac glycosides decrease activity of immune checkpoint protein 
IDO1 in cancer cells. 













































































































































































































































IDO1 activity IC50 A549 MDA-MB-231
ouabain 17 nM 89 nM
digoxin 40 nM ~164 nM
TNF-α/IFN-γ stimulates IDO1 expression in lung cancer A549 and breast
cancer MDA-MB-231 cells.
Cardiac glycosides ouabain and digoxin inhibit kynurenine production 
in A549 and MDA-MB-231 cancer cells with a modest impact on cell survival.
Ouabain, but not digoxin, 
downregulates IDO1 expression in 
A549 and MDA-MB-231 cancer cells.
A) B) C)
A) Western blot of IDO1 in A549 and MDA-MB-231 cells +/- 25 ng/mL TNF-α/1000 U/mL IFN-γ stimulation. B) IDO1 assay cell titration for A549 and MDA-MB-231 
cells. Used 10,000 A549/well and 50,000 MDA-MB-231/well as seeding density in all following experiments. C) Representative kynurenine absorbance standard 
curve calculated from kynurenine standards in 0.5M HCl       .
Western blot of IDO1 expression in TNF-α/IFN-γ stimulated cells treated with cardiac glycosides. A549 cells were treated with 0.05% DMSO, 25 nM ouabain, 
or 25 nM digoxin (left panel). MDA-MB-231 cells were treated with 0.05% DMSO, 150 nM ouabain, or 150 nM digoxin (right panel). 
A)
A) Dose-response curves for ouabain and digoxin treatment of TNF-α/IFN-γ stimulated A549 cells. B) Alamar Blue survival assay after 4h incubation with reagent. 
C) Comparison of IDO1 activity vs. viability as measured by Alamar Blue in A549 cells. D) Dose-response curves for ouabain and digoxin treatment of TNF-α/IFN-γ
stimulated MDA-MB-231 cells. E) Alamar Blue survival assay after 4h incubation with reagent. F) Comparison of IDO1 activity vs. viability as measured by Alamar 
Blue in MDA-MB-231 cells. G) Calculated IDO1 activity IC50s from  fitting the dose-response curves by non-linear least squares regression.
B) C)
D) E) F)












































(1) Transfer 150 μL supernatant to a 
round-bottom plate. 
+10 μL 30% v/v trichloroacetic acid. 
























































































































































































































































































































































































































































*p<0.05 ANOVA,  Bonferroni multiple comparisons
Drug/toxin Target(s) Effect
4-aminopyridine Kv K+ channels Inhibitor
Amiloride ASIC channel Inhibitor
Benzamil Na+/Ca2+ exchanger, ENaC, TRPP3, TRPA1 channels Inhibitor
Bupivacaine Nav, K2P channels Inhibitor
Carvedilol Kv1.5, Kir2.3 K+ channels, adrenoceptors Inhibitor
Celecoxib L-type Ca2+ and Kv7 channels both
Diclofenac (sodium) Kv7 channels Activator
Eslicarbazepine acetate VGSC Inhibitor
Flunarizine dihydrochloride L-type and T-type Ca2+ channels Inhibitor
Fluoxetine hydrochloride Kv4.3 channels Inhibitor
Iberiotoxin KCa1.1 K+ channels Inhibitor
Memantine hydrochloride NMDA receptor Inhibitor
Nifedipine L-type Ca2+ channels Inhibitor
NS-1619 KCa1.1 K+ channels Activator
Ouabain Na+/K+ ATPase Inhibitor
Phenytoin VGSC, HERG Inhibitor
Tetraethyl-ammonium chloride K+ channels - all Inhibitor
Tetrodotoxin VGSC Inhibitor
TRAM-34 KCa3.1 K+ channels Inhibitor
Veratridine VGSC Activator
1-EBIO KCa3.1, KCa2 channels Activator
Capsaicin TRPV1 channels Inhibitor
Carbenoxolone Pannexin-1 (Gap junction channel) Inhibitor
Cariporide NHE1 Inhibitor
Charybdotoxin KCa1.1, Kv1.2, Kv1.3 K+ channels Inhibitor
Gabapentin VGCC / alpha-2-delta Inhibitor
Glibenclamide TRPA1, KATP channels Inhibitor
Icilin TRPM8 channel Activator
Loperamide hydrochloride L-type, T-type Ca2+, HCN channels, NMDA, μ-opioid receptorsInhibitor
Margatoxin Kv1.3, Kv1.6 Inhibitor
Ranolazine VGSC Inhibitor
Ion channel drug screen of IDO1 activity G)
A library of 31 compounds targeting ion channels or 
pumps was screened in the kynurenine assay measuring IDO1 
activity in TNF-α/IFN-γ stimulated lung cancer (A549) and breast 
cancer (MDA-MB-231) cells. Points (right panel) represent 
technical replicates and data are normalized to their respective 





Stimulate with 25 ng/mL TNF-α
and 1000 U/mL IFN-γ
Day 3
Kynurenine, Alamar Blue assays
(after removing supernatant in step (1) Add 10 uL Alamar Blue to cells in tissue 
culture plate. Incubate 4h 37C/5% CO2. Measure absorbance at 570 nm, 600 nm.
Alamar Blue assay
Kynurenine assay of IDO1 activity
(2) Centrifuge 10 min/3000 rpm/room temperature. 
Transfer 100 μL to new plate.
(3) +100 μL 1.2% w/v Ehrlich’s reagent
in acetic acid. Room temperature/10 min
(4) Measure absorbance at 492 nm.
